naa a22 4500 510764142 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s12094-012-0979-8 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0979-8 Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel [Elektronische Daten] [J. Gao, Q. He, D. Hua, Y. Mao, Y. Li, L. Shen] Purpose: Capecitabine-containing chemotherapy was widely used in clinic medication. We investigated the association of the thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD) polymorphisms with the clinical outcome of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. Methods: Blood samples were collected prior to treatment from 125 patients with advanced gastric cancer and the TS (two or three repeats of a 28bp sequence in 5′-untranslated region and 6bp insertion or deletion in 3′-untranslated region), MTHFR (C677T) and DPD (IVS14+1G>A) polymorphisms were determined using PCR amplification and Sanger sequencing. Results: The median age of 125 patients was 58years (range, 23-76) with female 42 and male 83, and the response rate, median progression-free survival and overall survival (OS) were 43.2%, 5.2 and 11.0months. The median OS in patients with TS ins6/ins6 genotype (6.8months) was significantly shorter than those in patients with ins6/del6 (11.0months, P=0.016) and del6/del6 (11.5months, P=0.039) genotypes. Cox multivariate analysis also showed that TS ins6/ins6 genotype was the independent poor OS predictor (P=0.001, HR=3.182). No significant associations were found between the polymorphisms of TS 5′-UTR/MTHFR and clinical outcome, and no IVS14+1G>A polymorphism of DPD was found in this study. Conclusions: We first reported that TS 3′-UTR ins6/ins6 genotype could predict the poor survival of advanced gastric cancer patients treated with capecitabine plus paclitaxel, which would be further verified in a large multicenter study. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Advanced gastric cancer nationallicence Thymidylate synthase nationallicence Polymorphism nationallicence Capecitabine nationallicence Gao J. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut He Q. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut Hua D. Department of Medical Oncology, The Fourth People's Hospital of Wuxi, 214062, Wuxi, China aut Mao Y. Department of Medical Oncology, The Fourth People's Hospital of Wuxi, 214062, Wuxi, China aut Li Y. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut Shen L. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 619-625 1699-048X 15:8<619 2013 15 12094 https://doi.org/10.1007/s12094-012-0979-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0979-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gao J. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut NATIONALLICENCE 700 1- He Q. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut NATIONALLICENCE 700 1- Hua D. Department of Medical Oncology, The Fourth People's Hospital of Wuxi, 214062, Wuxi, China aut NATIONALLICENCE 700 1- Mao Y. Department of Medical Oncology, The Fourth People's Hospital of Wuxi, 214062, Wuxi, China aut NATIONALLICENCE 700 1- Li Y. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut NATIONALLICENCE 700 1- Shen L. Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, 100142, Beijing, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 619-625 1699-048X 15:8<619 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer